OTCMKTS:CHGCY Chugai Pharmaceutical Q1 2025 Earnings Results & Report $19.96 -0.01 (-0.05%) As of 03:58 PM Eastern Chugai Pharmaceutical reported Q1 2025 earnings on April 24, 2025. The company reported EPS of $0.19, while revenue was $1.89 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateApril 24, 2025TimeBefore Market Opens Chugai Pharmaceutical EPS ResultsActual EPS$0.19Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AChugai Pharmaceutical Revenue ResultsActual Revenue$1.89 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsChugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Chugai Pharmaceutical Q1 2025 Earnings FAQ Did Chugai Pharmaceutical beat earnings estimates for Q1 2025? Chugai Pharmaceutical (OTCMKTS:CHGCY) reported earnings of $0.19 per share for Q1 2025. The report was announced on Thursday, April 24, 2025. What was Chugai Pharmaceutical's revenue for Q1 2025? Chugai Pharmaceutical reported revenue of $1.89 billion for Q1 2025. When is Chugai Pharmaceutical's next earnings date? Chugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026. MarketBeat tracks confirmed and estimated earnings dates for Chugai Pharmaceutical on the company's earnings history page. Chugai Pharmaceutical Earnings HeadlinesCHGCY - Chugai Pharmaceutical Co., Ltd.October 12, 2026 | seekingalpha.comChugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week Low - Should You Sell?October 12, 2026 | americanbankingnews.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 16 at 1:00 AM | Weiss Ratings (Ad)Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month Low - Here's What HappenedOctober 6, 2026 | americanbankingnews.comChugai Pharmaceutical Co. Ltd. ADRAugust 19, 2026 | wsj.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comSee More Chugai Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email. Email Address About Chugai PharmaceuticalChugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization. Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer. The company also develops antibody-based therapies and other biologic and small-molecule medicines. Founded in 1925 and headquartered in Tokyo, Chugai operates primarily in Japan while serving international markets through its global business and strategic relationship with Roche. Chugai and Roche have maintained a strategic alliance since 2002, under which Roche distributes certain Chugai-developed products internationally and Chugai markets selected Roche products in Japan. Chugai is listed in Japan, and its American depositary shares trade over the counter under the symbol CHGCY.View Chugai Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
